EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity

Camille Mailho, Benoit Peyronnet, Marianne De Seze, Alexia Even, Maire-Aimée Perrouin-Verbe, Gérard Amarenco, Emmanuel Chartier-Kastler, Loic Le Normand, Andrea Manunta, Gilles Karsenty, Jacques Kerdraon, Alain Ruffion und 7 weitere

Neurourology and Urodynamics · 2024

DOI: 10.1002/nau.25427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurourology and Urodynamics, 2024. Verfasst von Camille Mailho und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Renal Transplantation and Andrology, Rangueil University Hospital, Toulouse, France. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Neuromuscular Agents, Urinary Bladder, Neurogenic, Urinary Bladder, Overactive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neurogenic detrusor overactivity (NDO) has a major impact on patients' quality of life and can lead to upper urinary tract complications. Intradetrusor botulinum toxin type A injections are administered as second‐line treatment to these patients following the failure of anticholinergic agents. The aim of the DETOX 2 study is to propose a consensus definition of the failure of intradetrusor botulinum toxin injections for NDO in patients presenting spinal cord injury, spina bifida, or multiple sclerosis (MS) with self‐catheterization.

Method

This study followed the method adopted by the French National Authority for Health for recommendations by consensus. Based on a review of the literature and a preliminary survey, a steering committee compiled a questionnaire and selected a rating group comprising 16 experts from the Neuro‐Urology Committee of the French Urology Association (cnuAFU) and Genulf. The experts were asked to complete the online questionnaire. At the end of the first round, all participants came together to discuss any disagreements and a second‐round online questionnaire was completed to reach a consensus.

Results

Thirteen of the 16 experts approached completed both rounds of questionnaires. A strong consensus was reached for two proposals (median score = 9/10) which were therefore included in the definition from the first round: at least one repeat injection of the same botulinum toxin at the same dose must be given to rule out failure on technical grounds and a duration of efficacy 40 cm H 2 O and/or a compliance issue and/or persistence of urinary incontinence and/or urgency and/or a number of daily self‐catheterizations >8/day and/or efficacy

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ANeuromuscular AgentsUrinary Bladder, NeurogenicUrinary Bladder, OveractiveUrinary IncontinenceHumansQuality of LifeTreatment OutcomeUrodynamics

Stichwörter der Autor:innen

botulinum toxinfailureintradetrusor injections of botulinum toxinneurological detrusor overactivity

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Urology, Renal Transplantation and Andrology, Rangueil University Hospital, Toulouse, France.
  • Department of Urology, University of Rennes, Rennes, France.
  • NeuroUrologie et Pelviperinéologie, Clinique Saint Augustin, Bordeaux, France.
  • Department of Rehabilitation and Physical Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Raymond Poincaré Academic Hospital, Université Paris-Saclay, Garches, France.
  • Department of Urology, Nantes University Hospital, Carrefour City, France.
  • GRC 01, Groupe de Recherche Clinique en Neuro-Urologie (GREEN), AP-HP, Hôpital Tenon, Sorbonne Université, Paris, France.

Zitieren

APA

Mailho, C., Peyronnet, B., De Seze, M., Even, A., Perrouin-Verbe, M. A., Amarenco, G., Chartier-Kastler, E., Le Normand, L., Manunta, A., Karsenty, G., Kerdraon, J., Ruffion, A., Saussine, C., Le Breton, F., Bernuz, B., Castel-Lacanal, E., Denys, P., Phé, V., & Gamé, X. (2024). How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25427

Vancouver

Mailho C, Peyronnet B, De Seze M, Even A, Perrouin-Verbe MA, Amarenco G, et al. How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity. Neurourology and Urodynamics. 2024. doi:10.1002/nau.25427

BibTeX
@article{Mailho2024,
  author = {Mailho, Camille and Peyronnet, Benoit and De Seze, Marianne and Even, Alexia and Perrouin-Verbe, Maire-Aimée and Amarenco, Gérard and Chartier-Kastler, Emmanuel and Le Normand, Loic and Manunta, Andrea and Karsenty, Gilles and Kerdraon, Jacques and Ruffion, Alain and Saussine, Christian and Le Breton, Frédérique and Bernuz, Benjamin and Castel-Lacanal, Evelyne and Denys, Pierre and Phé, Véronique and Gamé, Xavier},
  title = {How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity},
  journal = {Neurourology and Urodynamics},
  year = {2024},
  doi = {10.1002/nau.25427}
}
Kostenlos starten →